Study to Evaluate the Efficacy and Safety of Risperidone in Situ Microparticle (ISM)® in Patients With Acute Schizophrenia

Acute Schizophrenia Clinical Trial

— PRISMA-3  

Official title:

Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intramuscular Injections of Risperidone ISM® in Patients With Acute Exacerbation of Schizophrenia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03160521
• Other study ID #: ROV-RISP-2016-01
• Status: Completed
• Phase: Phase 3
• Start date: June 2, 2017
• Est. completion date: December 17, 2018

Study information

• Verified date: January 2022
• Source: Rovi Pharmaceuticals Laboratories
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multicenter, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of intramuscular (IM) injections of Risperidone ISM® (75 or 100 mg) or placebo, in patients with acute exacerbation of schizophrenia.

Description:

The study design includes a screening period, a 12-week treatment period, and a follow-up period. Eligible patients will be randomly assigned, under double-blind conditions, to receive the following study drug treatments in a 1:1:1 ratio during the double-blind treatment period: Risperidone ISM® 75 mg, Risperidone ISM® 100 mg, or placebo. The IM study drug (double-blind active Risperidone ISM® or placebo) will be administered in a deltoid or gluteal muscle for a total of 3 times, once every 4 weeks, during the 12-week treatment period. If indicated for an individual patient, prohibited medications may be washed out during the screening period. Patients who have never taken Risperidone must have a brief trial of oral Risperidone in order to ensure a lack of any clinically significant hypersensitivity reactions before the first dose of the study drug is administered. Efficacy will be assessed by describing changes in scores on standard psychiatric assessment tools at each visit. Safety assessments will also be conducted at each visit. The primary objective of this study is the following: • To evaluate the efficacy of Risperidone ISM as compared with that of placebo in the treatment of patients with acute exacerbation of schizophrenia The secondary objectives of this study are the following: - To characterize safety and tolerability of Risperidone ISM as compared with that of placebo in patients with acute exacerbation of schizophrenia - To quantify healthcare resource utilization (HRU), health-related quality of life (HRQL), and social functioning in patients treated with Risperidone ISM versus placebo for an acute exacerbation of schizophrenia - To explore pharmacokinetic characteristics of Risperidone ISM and associations with efficacy Patients who complete planned double-blind study drug treatments and study evaluations may be eligible to participate in an optional long-term extension segment of the study in which treatment with open-label Risperidone ISM 75 or 100 mg (randomly assigned) would begin immediately; for patients who do not participate in the extension segment, a safety follow-up phone contact will occur after the end-of-treatment visit. In addition to patients continuing from the double-blind segment of the study (rollover patients), patients not previously enrolled in the study (de novo patients) may be eligible to enter the long-term extension segment of the study. These patients will be evaluated for eligibility at a screening visit and, if eligible, will be allocated to receive either 75 or 100 mg Risperidone ISM every 4 weeks for approximately 12 months.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 438
• Est. completion date: December 17, 2018
• Est. primary completion date: December 17, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

To be eligible for enrolment into the study, each patient must meet all of the following

criteria at screening:

1. Capable of providing informed consent

1. A signed informed consent form must be provided before any study assessments are performed

2. Patients must be fluent in the language that is spoken by the investigator and the study site staff (including raters) and must be able to read and understand the words in which the informed consent is written

2. Age = 18 and = 65 years

3. Body mass index 18.5 to 40.0 kg/m2 (inclusive)

4. Current diagnosis of schizophrenia, according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria

1. Currently experiencing an acute exacerbation or relapse with onset < 2 months before screening

2. If inpatient at screening, has been hospitalized for < 2 weeks for the current exacerbation

3. = 2 years have elapsed since initial onset of active-phase schizophrenia symptoms

5. Has been able to achieve outpatient status for > 4 months during the past year

6. Has previously had a clinically significant beneficial response (improvement in schizophrenia symptoms), as determined by the investigator, to treatment with an antipsychotic medication other than clozapine

7. Agrees to discontinue prohibited medications as applicable and as clinically indicated according to investigator instructions

8. Dosages of all permitted medications are considered to have been stable (with the exception of medication to be used on an as-needed basis) for = 2 weeks prior to the baseline visit and to remain stable during participation in this study

9. Positive and Negative Syndrome Scale (PANSS) results at the screening and baseline visits meets the following criteria: a. Total score between 80 and 120, inclusive b. Score of = 4 (moderate or greater) for = 2 of the following Positive Scale items: i. Item 1 (P1: delusions) ii. Item 2 (P2: conceptual disorganization) iii. Item 3 (P3: hallucinatory behavior) iv. Item 6 (P6: suspiciousness/persecution)

10. Clinical Global Impression - Severity (CGI-S) score of = 4 (moderately ill or worse)

11. Resides in a stable living situation and is anticipated to return to that same stable living situation after discharge from the inpatient study unit, in the opinion of the investigator

12. Has an identified reliable informant who is anticipated to remain the same after the patient is discharged from the inpatient study unit, in the opinion of the investigator

13. Meets the following criteria:

a. If a sexually active, is using a medically accepted contraceptive method, and will continue to use such throughout participation in this study (and for = 6 months after the last dose of IM study drug has been administered); acceptable methods include the following: i. Condoms (male or female) with or without a spermicidal agent ii. Diaphragm or cervical cap with spermicide iii. Intrauterine device iv. Hormonal contraceptive b. If not currently sexually active, them meets the following criteria: i. Agrees that if sexually activity resumes while participating in this study, a medically accepted contraception method will be used

14. Willing and able to be confined to an inpatient study unit for up to 2 weeks (or longer if clinically indicated), as applicable and as clinically indicated according to investigator instructions

15. Agrees not to post any personal medical data related to the study or information related to the study on any website or social media site (eg, Facebook, Twitter, and others) during the study duration Exclusion Criteria: An individual who meets any of the following criteria at screening will not be permitted to

enroll in the study:

1. History of proven inadequate clinical response to treatment with therapeutic doses (with good compliance) of risperidone or paliperidone

2. History of treatment resistance, defined as failure to respond to 2 discrete adequate trials (= 4 weeks with an adequate dose) of 2 different antipsychotic medications; history of clozapine use (exception: use was not because of treatment resistance or refractory psychotic symptoms)

3. Improvement in PANSS total score 20% or greater between the initial screening visit and first injection

4. Known or suspected intolerance of or allergy or hypersensitivity to risperidone, paliperidone, or any of the excipients in the IM formulations of these

5. History of neuroleptic malignant syndrome, clinically significant tardive dyskinesia, or tardive dystonia

6. History of any other medical condition that is considered to pose any unjustifiable risk or interfere with study assessments

7. Clinically significant extrapyramidal symptoms at screening or baseline

8. Answer of "yes" on item 4 or on item 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) (ideation) with the most recent episode occurring within the past 2 months, or answer "yes" to any of the 5 items (behavior) with an episode occurring within the last year

9. Current diagnosis or a history of substance use disorder according to DSM-5 criteria within 6 months prior to the screening visit (with the exception of tobacco, mild cannabis, or mild alcohol use disorder) or a positive drug screen test (with the exception of cannabis) verified by repeat testing

10. Lifetime history of diagnosis of schizoaffective disorder or bipolar disorder

11. Clinically significant comorbid neuropsychiatric disorders including any of the

following:

1. Current untreated or unstable major depressive disorder

2. Clinically significant cognitive difficulties including dementia, delirium, or amnesic syndrome, within the past 2 years and would interfere with participation in the study

3. Any other psychiatric condition that would, in the judgment of the investigator, interfere with participation in the study

12. Clinically significant or unstable medical illness/condition/disorder that would be anticipated, in the investigator's opinion, to potentially compromise patient safety or adversely affect the evaluation of efficacy, including (but not necessarily limited

to) the following:

1. Clinically significant hypotension or hypertension not stabilized by medical therapy (diastolic blood pressure > 105 mmHg)

2. Unstable thyroid dysfunction in the past 6 months

3. Malignant tumor within the last 5 years

4. Neurologic conditions including the following:

i. History of seizure disorder or condition associated with seizures ii. History of brain tumor, subdural hematoma, or other clinically significant neurological condition within the past 12 months iii. Head trauma with loss of consciousness within 12 months before screening iv. Active acute or chronic central nervous system infection v. Stroke within 6 months before screening e. Cardiac conditions including the following: i. Clinically significant cardiac arrhythmia, cardiomyopathy, or cardiac conduction defect ii. History of myocardial infarction or unstable angina within the last 3 months before screening, or clinically significant abnormality on screening or baseline electrocardiogram (ECG) including but not limited to the following: QT interval corrected for heart rate using Fridericia's formula (QTcF) > 465 msec if male or > 485 msec if female

13. Laboratory abnormality that, in the opinion of the investigator, would compromise the well-being of the patient, or any of the following laboratory abnormalities at

screening or baseline:

1. Aspartate aminotransferase or alanine aminotransferase value = 2 times the upper limit of the laboratory normal reference range

2. Hemoglobin A1c > 9%

3. Absolute neutrophil count = 1.5 × 103 µL

4. Platelet count = 75 × 103 µL

5. Creatinine clearance < 60 mL/min

6. Positive test result for human immunodeficiency virus, hepatitis B surface antigen, or antihepatitis C virus antibody

7. Positive pregnancy test result

8. Urine drug screen at screening or baseline shows a positive result for any of the tested substances (potential exceptions: results positive for benzodiazepine may not be exclusionary if the investigator confirms that such medication was medically indicated and consults the medical monitor before enrolling a patient with such a finding; results positive for Tetrahydrocannabinol (THC) may not be exclusionary in certain cases only if exclusion criterion 9 is not met and only if the medical monitor provides approval)

14. Pregnant, lactating, or breastfeeding

15. Inadequate gluteal or deltoid musculature or excessive fat, as determined by the investigator, that would interfere with IM study drug injections

16. Any contraindication for IM injections

17. Receipt of any long-acting antipsychotic medication by IM injection within 60 days before screening

18. Current involuntary hospitalization or incarceration

19. Hospitalized for more than 30 days during the 90 days before screening

20. Participation in another clinical study in which the patient received an experimental or investigational drug or agent within 6 months before screening

21. Participation in a clinical study with Risperidone ISM within 1 year before screening

22. Study site personnel and/or persons employed by the investigator or study site or is an immediate family member of such persons

23. Patients taking any prohibited concomitant medication (see Section 3.2.2.1.1) at the time of randomization visit

24. Clinically significant ocular disease or visual impairment interfering with the planned ophthalmological examinations or that in the investigator's opinion could potentially compromise patients' ocular safety

25. Patients with planned or anticipated need for ocular surgery during the treatment period of the trial

Related Conditions & MeSH terms

• Acute Schizophrenia
• Schizophrenia

Intervention

Drug:
• Risperidone ISM 75 mg
Monthly (once every 4 weeks) IM injection in the gluteal or deltoid muscle.
• Risperidone ISM 100 mg
Monthly (once every 4 weeks) IM injection in the gluteal or deltoid muscle.
• Placebo of Risperidone ISM
Monthly (once every 4 weeks) IM injection in the gluteal or deltoid muscle.

Locations

Country	Name	City	State
Ukraine	Regional Clinical Hospital n.a I.I. Mechnicov	Dnipro
Ukraine	Kharkiv Regional Clinical Psychiatric Hospital	Kharkiv
Ukraine	Public Healthcare Institution "Kharkiv Regional Clinical Psychiatric Hospital No. 3", Center of Urgent Psychiatry	Kharkiv
Ukraine	Kherson Regional Psychiatric Hospital	Kherson
Ukraine	Kiev City Psychiatric Hospital No. 2	Kiev
Ukraine	Kyiv Regional Medical Association "Psykhiatriya" in Kyiv	Kiev
Ukraine	CI Lviv Regional Clinical Psychiatric Hospital. Department 20	Lviv
Ukraine	CI Lviv Regional Clinical Psychiatric Hospital. Department 25	Lviv
Ukraine	Odesa Regional Medical Centre of Mental Health	Odesa
Ukraine	Maltsev Regional Clinical Psychiatric Ho	Poltava
Ukraine	N.I. Pyrogov Vinnytsya Natl Medical University	Vinnytsia
United States	Atlanta Center for Medical Research	Atlanta	Georgia
United States	Community Clinical Research Inc.	Austin	Texas
United States	Hassman Research Institute	Berlin	New Jersey
United States	CIMU Bellflower	Cerritos	California
United States	Carolina Clinical Triasl Inc	Charleston	South Carolina
United States	Midwest Clinical Research Center	Dayton	Ohio
United States	InSite Clinical Research	DeSoto	Texas
United States	Precise Research Centers MS	Flowood	Mississippi
United States	CBH Health LLC	Gaithersburg	Maryland
United States	Collaborative Neuroscience Network, LLC.	Garden Grove	California
United States	Galiz Research	Hialeah	Florida
United States	Innovative Clinical Research Inc.	Hollywood	Florida
United States	Altea Research Institute	Las Vegas	Nevada
United States	Synergy Research San Diego	Lemon Grove	California
United States	Apostle Clinical Trials	Long Beach	California
United States	NRC Research Institute	Orange	California
United States	CNRI-Los Angeles LLC	Pico Rivera	California
United States	Pillar Clinical Research LLC	Richardson	Texas
United States	Woodland Research Northwest	Rogers	Arkansas
United States	CNRI-San Diego	San Diego	California

Sponsors (1)

Lead Sponsor	Collaborator
Rovi Pharmaceuticals Laboratories

Countries where clinical trial is conducted

United States,  Ukraine, 

References & Publications (1)

Correll CU, Litman RE, Filts Y, Llaudó J, Naber D, Torres F, Martínez J. Efficacy and safety of once-monthly Risperidone ISM(®) in schizophrenic patients with an acute exacerbation. NPJ Schizophr. 2020 Nov 25;6(1):37. doi: 10.1038/s41537-020-00127-y. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	PSP Total Score From Baseline at Each Post-baseline Assessment Time Point	Personal and Social Performance Scale (PSP) total score mean change from baseline at each post-baseline assessment time point.; The PSP is a 100-point single-item rating scale that is based on 4 domains: family and social functioning, self-care, work and socially useful activities, and disturbing and aggressive behaviors. Each domain is rated in 6 degrees of severity (absent, mild, manifest, marked, severe, very severe). On the PSP scale, higher scores indicate better social functioning: 71-100 indicates mild to no functional impairment; 31-70 varying degrees of disability and 1-30, minimal functioning needing intense support and/or supervision. Participants with a PSP total score of 71 to 100 were considered to have mild functional difficulty. Scores of 31 to 70 represented varying degrees of disability (31 to 70) and ratings of 1 to 30 indicated minimal functioning that required intense support and/or supervision.	Day 1 (Baseline), Days 29, 57 and 85 (or the last post-baseline assessment)
Other	SWN-20 Total Score From Baseline at Each Post-baseline Assessment Time Point	20-item Subjective Well-Being Under Neuroleptics Treatment Scale (SWN-20) total score mean change from baseline at each post-baseline assessment time point.; The SWN is a 38-item instrument to measure subjective effects of neuroleptic medications in patients with schizophrenia and consists of 20 positive statements and 18 negative statements. The short form of the SWN, the 20-item SWN-20, was developed in order to allow for quick assessment of subjective side effects in a clinical setting. Like in the original SWN, with the SWN-20 the patient is asked to rate well-being items that have been identified as related to antipsychotic treatment on a 6-point scale ranging from "Not at all" to "Very much." The SWN-20 is scored on a scale ranging from 20 to 120, with higher scores indicating better health-related quality of life (HRQL). The SWN-20 contains five 4-item subscales: mental functioning, self-control, emotional regulation, physical functioning, and social integration. Eac	Day 1 (Baseline), Days 29, 57 and 85 or the last post-baseline assessment
Other	Plasma PK Parameters	Plasma PK Parameters of Risperidone Active Moiety; Cmax values are estimated and based on the plasma level of Day 3 for each dosing Interval; Cmin are the trough levels of Day 29, which is at the end of each dosing Interval;	Day 3 and Day 29 after Dose 1, 2 and 3
Primary	PANSS Total Score Mean Change From Baseline to Endpoint	The Positive and Negative Syndrome Scale (PANSS) is a 30-item clinician-rated instrument for assessing the symptoms of schizophrenia.The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score is the sum of all 30 PANSS items and ranges from 30 to 210, with 30 indicating absence of symptoms of schizophrenia and 210 indicating extreme ratings of all 30 symptoms. Negative change from baseline scores indicate improvements in symptoms whereas higher scores mean a worse outcome.; Endpoint is defined as study day 85 or the last post-baseline assessment if early discontinuation.	Day 1 (Baseline) and Day 85 (or the last post-baseline assessment)
Secondary	CGI-S Total Score Mean Change From Baseline to Endpoint	The Clinician Global Impression - Severity (CGI-S) score is a 7-point clinician-rated scale for assessing the global severity of the illness. A rating of 1 is equivalent to "Normal, not at all ill" and a rating of 7 is equivalent to "Among the most extremely ill participants". Negative change from baseline scores indicate improvement in the severity of illness whereas higher scores mean a worse outcome.; Endpoint is defined as study day 85 or the last post-baseline assessment if early discontinuation.	Day 1 (Baseline) and Day 85 (or the last post-baseline assessment)
Secondary	CGI-I Score Mean at Endpoint	The Clinical Global Impression - Improvement (CGI-I) Score consists of a single 7-point rating score total improvement, regardless of whether or not the change it is due entirely to drug treatment.; Scores are: 1, Very much improved; 2, Much improved; 3, Minimally improved; 4, No change; 5, Minimally worse; 6, Much worse; or 7, Very much worse.; Endpoint is defined as study day 85 or the last post-baseline double-blind assessment if early discontinuation.	Day 1 (Baseline) and Day 85 (or the last post-baseline assessment)
Secondary	Overall Response Rate at Endpoint	Overall response was defined as either PANSS total score = 30% decrease from baseline, or CGI-I score of 2 (much improved) or 1 (very much improved).; Endpoint is defined as study day 85 or the last post-baseline assessment if early discontinuation.	Day 85 or the last post-baseline assessment
Secondary	PANSS Response Rate at Endpoint	The definition of Positive and Negative Syndrome Scale (PANSS) response was a decrease from baseline in PANSS total score of = 30% (improvement of symptoms).; Endpoint is defined as study day 85 or the last post-baseline double-blind assessment if early discontinuation.	Day 85 or the last post-baseline assessment
Secondary	PANSS Positive Subscale Mean Change From Baseline to Endpoint	The PANSS consisted of three subscales that contained a total of 30 symptom constructs. For each symptom construct, severity is rated on a 7-point scale, with a score of 1 indicated the absence of symptoms and a score of 7 indicated extremely severe symptoms. In positive subscale, the 7 positive symptom constructs were: delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility.; PANSS Positive Subscale Score ranges from 7 (absence of symptoms) to 49 (extremely severe symptoms).; Endpoint is defined as study day 85 or the last post-baseline assessment if early discontinuation.	Day 1 (Baseline) and Day 85 (or the last post-baseline assessment)
Secondary	PANSS Negative Subscale Mean Change From Baseline to Endpoint	The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicated- absence of symptoms and a score of 7 indicated- extremely severe symptoms. The PANSS negative subscale score was the sum of the rating scores for the 7 negative scale items from the PANSS panel. The 7 negative symptom constructs were: blunted affect, emotional withdrawal, poor rapport, passive apathetic withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation and stereotyped thinking. PANSS Negative Subscale Score ranges from 7 (absence of symptoms) to 49 (extremely severe symptoms).; Endpoint is defined as study day 85 or the last post-baseline assessment if early discontinuation.	Day 1 (Baseline) and Day 85 (or the last post-baseline assessment)
Secondary	PANSS General Psychopathology Subscale Mean Change From Baseline to Endpoint	The PANSS consisted of three subscales that contained a total of 30 symptom constructs. For each symptom construct, severity is rated on a 7-point scale, with a score of 1 indicated the absence of symptoms and a score of 7 indicated extremely severe symptoms. The general psychopathology scale consists of 16 items which measure somatic concern, anxiety, guilt feelings, tension, mannerisms and posturing, depression, motor retardation, uncooperativeness, unusual thought content, disorientation, poor attention, lack of judgment and insight, disturbance of volition, poor impulse control, preoccupation and active social avoidance. PANSS General Psychopathology Subscale Score ranges from 16 (absence of symptoms) to 112 (extremely severe symptoms).; Endpoint is defined as study day 85 or the last post-baseline assessment if early discontinuation.	Day 1 (Baseline) and Day 85 (or the last post-baseline assessment)